ADVB (Advanced Biomed) Debt-to-Equity: 0.00 (As of Mar. 2026)


ADVB Advanced Biomed Inc ADVB
12 GF Score
Price $5.16
! 1 Warning Sign
View Full Analysis

What is Advanced Biomed Debt-to-Equity?

Advanced Biomed ADVB -3.10% 12 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 183 Medical Diagnostics & Research companies, Advanced Biomed ranks worse than 546447.54% on this metric.

Advanced Biomed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.02 Mil. Advanced Biomed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.01 Mil. Advanced Biomed's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $9.21 Mil. Advanced Biomed's debt to equity for the quarter that ended in Mar. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Advanced Biomed's Debt-to-Equity or its related term are showing as below:

During the past 5 years, the highest Debt-to-Equity Ratio of Advanced Biomed was 0.66. The lowest was 0.00. And the median was 0.10.

ADVB's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.33
* Ranked among companies with meaningful Debt-to-Equity only.

Advanced Biomed  (NAS:ADVB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Advanced Biomed Debt-to-Equity Related Terms

Advanced Biomed Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Advanced Biomed's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Biomed Debt-to-Equity Chart

Advanced Biomed Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Equity
0.01 0.13 0.18 0.08 0.01

Advanced Biomed Quarterly Data
Jun21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.01 0.01 0.00 0.00

ADVB vs MBAI, XWEL, NDRA: Debt-to-Equity Comparison

For the Diagnostics & Research subindustry, Advanced Biomed's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Biomed Debt-to-Equity vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Advanced Biomed's Debt-to-Equity falls into.


ADVB
12GF Score
Advanced Biomed Inc ADVB
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Biomed Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Advanced Biomed's Debt to Equity Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.036 + 0.006) / 3.478
=0.01

Advanced Biomed's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.019 + 0.011) / 9.21
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Advanced Biomed (ADVB) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry.
Is Advanced Biomed's Debt-to-Equity too high?
Advanced Biomed's current Debt-to-Equity is 0.00. Based on the distribution chart, Advanced Biomed ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Debt-to-Equity compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #999999 out of 183 companies for Debt-to-Equity. This places Advanced Biomed in the lower half of its industry. The industry median Debt-to-Equity is 0.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Advanced Biomed and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Biomed Business Description

Address No. 689-85 Xiaodong Road, Yongkang District, Tainan, TWN
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score

Get the complete analysis for ADVB

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.16
Price